Company Update (NASDAQ:BIIB): Biogen Idec Signs License Agreement With ... Jutia Group Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical ... |
